APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Retinal Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Long-acting Retinal Drugs Industry Growth and Trends Forecast to 2032

23 December 2025111 pages

Choose your research edition.

Industry ResearchLong-acting Retinal Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Retinal Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Long-acting Retinal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Retinal Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Retinal Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

According to APO Research, the global Long-acting Retinal Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Long-acting Retinal Drugs market include Janssen Pharmaceuticals (Johnson & Johnson), Takeda, Teva Pharmaceutical, Novartis, Merck, Bayer, Alcon Inc., AbbVie Inc. and ThromboGenics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Long-acting Retinal Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Long-acting Retinal Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Long-acting Retinal Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Long-acting Retinal Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Long-acting Retinal Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Long-acting Retinal Drugs Market by Company

Janssen Pharmaceuticals (Johnson & Johnson)

Takeda

Teva Pharmaceutical

Novartis

Merck

Bayer

Alcon Inc.

AbbVie Inc.

ThromboGenics

Regeneron

Oxurion NV

OncoGene Pharmaceuticals

MeiraGTx Limited

F. Hoffmann-La Roche

Bausch Health Co. Inc.

Allergan

Alimera Sciences Inc.

Long-acting Retinal Drugs Segment by Type

Chemically Synthesized Drugs

Biologics

Natural/Nutritional Supplements

Long-acting Retinal Drugs Segment by Application

Hospital

Clinic

Other

Long-acting Retinal Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Retinal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Retinal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Retinal Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Long-acting Retinal Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting Retinal Drugs Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Long-acting Retinal Drugs Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Long-acting Retinal Drugs Market Share by Region (2021-2026) Table 4. Global Long-acting Retinal Drugs Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Long-acting Retinal Drugs Market Share by Region (2027-2032) Table 6. Global Long-acting Retinal Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Long-acting Retinal Drugs Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Long-acting Retinal Drugs Market Size Share by Type (2021-2026) Table 9. Global Long-acting Retinal Drugs Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Long-acting Retinal Drugs Market Size Share Forecasted by Type (2027-2032) Table 11. North America Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Long-acting Retinal Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Long-acting Retinal Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Long-acting Retinal Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Long-acting Retinal Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Long-acting Retinal Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Long-acting Retinal Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Long-acting Retinal Drugs Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Long-acting Retinal Drugs Market Size Share by Application (2021-2026) Table 24. Global Long-acting Retinal Drugs Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Long-acting Retinal Drugs Market Size Share Forecasted by Application (2027-2032) Table 26. North America Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Long-acting Retinal Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Long-acting Retinal Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Long-acting Retinal Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Long-acting Retinal Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Long-acting Retinal Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Long-acting Retinal Drugs Industry Trends Table 37. Long-acting Retinal Drugs Industry Drivers Table 38. Long-acting Retinal Drugs Industry Opportunities and Challenges Table 39. Long-acting Retinal Drugs Industry Restraints Table 40. Global Long-acting Retinal Drugs Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Long-acting Retinal Drugs Revenue Market Share by Company (2021-2026) Table 42. Global Long-acting Retinal Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Long-acting Retinal Drugs Key Company Headquarters & Area Served Table 44. Global Long-acting Retinal Drugs Company, Product Type & Application Table 45. Global Long-acting Retinal Drugs Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Long-acting Retinal Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Janssen Pharmaceuticals (Johnson & Johnson) Company Information Table 49. Janssen Pharmaceuticals (Johnson & Johnson) Business Overview Table 50. Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Product Portfolio Table 52. Janssen Pharmaceuticals (Johnson & Johnson) Recent Development Table 53. Takeda Company Information Table 54. Takeda Business Overview Table 55. Takeda Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Takeda Long-acting Retinal Drugs Product Portfolio Table 57. Takeda Recent Development Table 58. Teva Pharmaceutical Company Information Table 59. Teva Pharmaceutical Business Overview Table 60. Teva Pharmaceutical Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Teva Pharmaceutical Long-acting Retinal Drugs Product Portfolio Table 62. Teva Pharmaceutical Recent Development Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Novartis Long-acting Retinal Drugs Product Portfolio Table 67. Novartis Recent Development Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Merck Long-acting Retinal Drugs Product Portfolio Table 72. Merck Recent Development Table 73. Bayer Company Information Table 74. Bayer Business Overview Table 75. Bayer Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Bayer Long-acting Retinal Drugs Product Portfolio Table 77. Bayer Recent Development Table 78. Alcon Inc. Company Information Table 79. Alcon Inc. Business Overview Table 80. Alcon Inc. Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Alcon Inc. Long-acting Retinal Drugs Product Portfolio Table 82. Alcon Inc. Recent Development Table 83. AbbVie Inc. Company Information Table 84. AbbVie Inc. Business Overview Table 85. AbbVie Inc. Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. AbbVie Inc. Long-acting Retinal Drugs Product Portfolio Table 87. AbbVie Inc. Recent Development Table 88. ThromboGenics Company Information Table 89. ThromboGenics Business Overview Table 90. ThromboGenics Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. ThromboGenics Long-acting Retinal Drugs Product Portfolio Table 92. ThromboGenics Recent Development Table 93. Regeneron Company Information Table 94. Regeneron Business Overview Table 95. Regeneron Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Regeneron Long-acting Retinal Drugs Product Portfolio Table 97. Regeneron Recent Development Table 98. Oxurion NV Company Information Table 99. Oxurion NV Business Overview Table 100. Oxurion NV Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Oxurion NV Long-acting Retinal Drugs Product Portfolio Table 102. Oxurion NV Recent Development Table 103. OncoGene Pharmaceuticals Company Information Table 104. OncoGene Pharmaceuticals Business Overview Table 105. OncoGene Pharmaceuticals Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Portfolio Table 107. OncoGene Pharmaceuticals Recent Development Table 108. MeiraGTx Limited Company Information Table 109. MeiraGTx Limited Business Overview Table 110. MeiraGTx Limited Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. MeiraGTx Limited Long-acting Retinal Drugs Product Portfolio Table 112. MeiraGTx Limited Recent Development Table 113. F. Hoffmann-La Roche Company Information Table 114. F. Hoffmann-La Roche Business Overview Table 115. F. Hoffmann-La Roche Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. F. Hoffmann-La Roche Long-acting Retinal Drugs Product Portfolio Table 117. F. Hoffmann-La Roche Recent Development Table 118. Bausch Health Co. Inc. Company Information Table 119. Bausch Health Co. Inc. Business Overview Table 120. Bausch Health Co. Inc. Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Bausch Health Co. Inc. Long-acting Retinal Drugs Product Portfolio Table 122. Bausch Health Co. Inc. Recent Development Table 123. Allergan Company Information Table 124. Allergan Business Overview Table 125. Allergan Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Allergan Long-acting Retinal Drugs Product Portfolio Table 127. Allergan Recent Development Table 128. Alimera Sciences Inc. Company Information Table 129. Alimera Sciences Inc. Business Overview Table 130. Alimera Sciences Inc. Long-acting Retinal Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Alimera Sciences Inc. Long-acting Retinal Drugs Product Portfolio Table 132. Alimera Sciences Inc. Recent Development Table 133. North America Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. North America Long-acting Retinal Drugs Market Size by Country (2021-2026) & (US$ Million) Table 135. North America Long-acting Retinal Drugs Market Share by Country (2021-2026) Table 136. North America Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. North America Long-acting Retinal Drugs Market Share Forecast by Country (2027-2032) Table 138. Europe Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Europe Long-acting Retinal Drugs Market Size by Country (2021-2026) & (US$ Million) Table 140. Europe Long-acting Retinal Drugs Market Share by Country (2021-2026) Table 141. Europe Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Europe Long-acting Retinal Drugs Market Share Forecast by Country (2027-2032) Table 143. Asia-Pacific Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Asia-Pacific Long-acting Retinal Drugs Market Size by Country (2021-2026) & (US$ Million) Table 145. Asia-Pacific Long-acting Retinal Drugs Market Share by Country (2021-2026) Table 146. Asia-Pacific Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Asia-Pacific Long-acting Retinal Drugs Market Share Forecast by Country (2027-2032) Table 148. Latin America Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Latin America Long-acting Retinal Drugs Market Size by Country (2021-2026) & (US$ Million) Table 150. Latin America Long-acting Retinal Drugs Market Share by Country (2021-2026) Table 151. Latin America Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Latin America Long-acting Retinal Drugs Market Share Forecast by Country (2027-2032) Table 153. Middle East & Africa Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Middle East & Africa Long-acting Retinal Drugs Market Size by Country (2021-2026) & (US$ Million) Table 155. Middle East & Africa Long-acting Retinal Drugs Market Share by Country (2021-2026) Table 156. Middle East & Africa Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Middle East & Africa Long-acting Retinal Drugs Market Share Forecast by Country (2027-2032) Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Long-acting Retinal Drugs Product Image Figure 3. Global Long-acting Retinal Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Long-acting Retinal Drugs Market Size (2021-2032) & (US$ Million) Figure 5. Global Long-acting Retinal Drugs Market Share by Region: 2025 VS 2032 Figure 6. Global Long-acting Retinal Drugs Market Share by Region (2021-2032) Figure 7. North America Long-acting Retinal Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Long-acting Retinal Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Long-acting Retinal Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Long-acting Retinal Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Long-acting Retinal Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Chemically Synthesized Drugs Image Figure 13. Global Chemically Synthesized Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Biologics Image Figure 15. Global Biologics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Natural/Nutritional Supplements Image Figure 17. Global Natural/Nutritional Supplements Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Long-acting Retinal Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Long-acting Retinal Drugs Market Share by Type 2025 VS 2032 Figure 20. North America Long-acting Retinal Drugs Market Size Share by Type (2021-2032) Figure 21. Europe Long-acting Retinal Drugs Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Long-acting Retinal Drugs Market Size Share by Type (2021-2032) Figure 23. Latin America Long-acting Retinal Drugs Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Long-acting Retinal Drugs Market Size Share by Type (2021-2032) Figure 25. Hospital Image Figure 26. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Clinic Image Figure 28. Global Clinic Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Other Image Figure 30. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Long-acting Retinal Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Long-acting Retinal Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Long-acting Retinal Drugs Market Size Share by Application (2021-2032) Figure 34. Europe Long-acting Retinal Drugs Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Long-acting Retinal Drugs Market Size Share by Application (2021-2032) Figure 36. Latin America Long-acting Retinal Drugs Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Long-acting Retinal Drugs Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Long-acting Retinal Drugs Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Long-acting Retinal Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Long-acting Retinal Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Long-acting Retinal Drugs Market Share by Country (2021-2032) Figure 43. Europe Long-acting Retinal Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Long-acting Retinal Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Long-acting Retinal Drugs Market Share by Country (2021-2032) Figure 46. Asia-Pacific Long-acting Retinal Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Long-acting Retinal Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Long-acting Retinal Drugs Market Share by Country (2021-2032) Figure 49. Latin America Long-acting Retinal Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Long-acting Retinal Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Long-acting Retinal Drugs Market Share by Country (2021-2032) Figure 52. Middle East & Africa Long-acting Retinal Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Long-acting Retinal Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Long-acting Retinal Drugs Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Chemically Synthesized Drugs
  • Biologics
  • Natural/Nutritional Supplements
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Takeda
  • Teva Pharmaceutical
  • Novartis
  • Merck
  • Bayer
  • Alcon Inc.
  • AbbVie Inc.
  • ThromboGenics
  • Regeneron
  • Oxurion NV
  • OncoGene Pharmaceuticals
  • MeiraGTx Limited
  • F. Hoffmann-La Roche
  • Bausch Health Co. Inc.
  • Allergan
  • Alimera Sciences Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Long-acting Retinal Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Long-acting Retinal Drugs Market Size by Region (2021-2032)
  5. 1.4.1 Global Long-acting Retinal Drugs Market Size by Region (2021-2026)
  6. 1.4.2 Global Long-acting Retinal Drugs Market Size by Region (2027-2032)
  7. 1.5 Key Regions Long-acting Retinal Drugs Market Size (2021-2032)
  8. 1.5.1 North America Long-acting Retinal Drugs Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Long-acting Retinal Drugs Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Long-acting Retinal Drugs Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Long-acting Retinal Drugs Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Long-acting Retinal Drugs Market Size Growth Rate (2021-2032)
2 Long-acting Retinal Drugs Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Chemically Synthesized Drugs
  3. 2.1.2 Biologics
  4. 2.1.3 Natural/Nutritional Supplements
  5. 2.2 Global Long-acting Retinal Drugs Market Size by Type
  6. 2.2.1 Global Long-acting Retinal Drugs Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Long-acting Retinal Drugs Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Long-acting Retinal Drugs Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Long-acting Retinal Drugs Market Size by Regions
  10. 2.3.1 North America Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Long-acting Retinal Drugs Market Size Breakdown by Type (2021-2026)
3 Long-acting Retinal Drugs Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Clinic
  4. 3.1.3 Other
  5. 3.2 Global Long-acting Retinal Drugs Market Size by Application
  6. 3.2.1 Global Long-acting Retinal Drugs Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Long-acting Retinal Drugs Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Long-acting Retinal Drugs Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Long-acting Retinal Drugs Market Size by Regions
  10. 3.3.1 North America Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Long-acting Retinal Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Long-acting Retinal Drugs Industry Trends
  2. 4.2 Long-acting Retinal Drugs Industry Drivers
  3. 4.3 Long-acting Retinal Drugs Industry Opportunities and Challenges
  4. 4.4 Long-acting Retinal Drugs Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Long-acting Retinal Drugs Revenue (2021-2026)
  2. 5.2 Global Long-acting Retinal Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Long-acting Retinal Drugs Key Company Headquarters & Area Served
  4. 5.4 Global Long-acting Retinal Drugs Company, Product Type & Application
  5. 5.5 Global Long-acting Retinal Drugs Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Long-acting Retinal Drugs Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Long-acting Retinal Drugs Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Long-acting Retinal Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Janssen Pharmaceuticals (Johnson & Johnson)
  2. 6.1.1 Janssen Pharmaceuticals (Johnson & Johnson) Company Information
  3. 6.1.2 Janssen Pharmaceuticals (Johnson & Johnson) Business Overview
  4. 6.1.3 Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Product Portfolio
  6. 6.1.5 Janssen Pharmaceuticals (Johnson & Johnson) Recent Developments
  7. 6.2 Takeda
  8. 6.2.1 Takeda Company Information
  9. 6.2.2 Takeda Business Overview
  10. 6.2.3 Takeda Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Takeda Long-acting Retinal Drugs Product Portfolio
  12. 6.2.5 Takeda Recent Developments
  13. 6.3 Teva Pharmaceutical
  14. 6.3.1 Teva Pharmaceutical Company Information
  15. 6.3.2 Teva Pharmaceutical Business Overview
  16. 6.3.3 Teva Pharmaceutical Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Teva Pharmaceutical Long-acting Retinal Drugs Product Portfolio
  18. 6.3.5 Teva Pharmaceutical Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Long-acting Retinal Drugs Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Merck
  26. 6.5.1 Merck Company Information
  27. 6.5.2 Merck Business Overview
  28. 6.5.3 Merck Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Merck Long-acting Retinal Drugs Product Portfolio
  30. 6.5.5 Merck Recent Developments
  31. 6.6 Bayer
  32. 6.6.1 Bayer Company Information
  33. 6.6.2 Bayer Business Overview
  34. 6.6.3 Bayer Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Bayer Long-acting Retinal Drugs Product Portfolio
  36. 6.6.5 Bayer Recent Developments
  37. 6.7 Alcon Inc.
  38. 6.7.1 Alcon Inc. Company Information
  39. 6.7.2 Alcon Inc. Business Overview
  40. 6.7.3 Alcon Inc. Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Alcon Inc. Long-acting Retinal Drugs Product Portfolio
  42. 6.7.5 Alcon Inc. Recent Developments
  43. 6.8 AbbVie Inc.
  44. 6.8.1 AbbVie Inc. Company Information
  45. 6.8.2 AbbVie Inc. Business Overview
  46. 6.8.3 AbbVie Inc. Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 AbbVie Inc. Long-acting Retinal Drugs Product Portfolio
  48. 6.8.5 AbbVie Inc. Recent Developments
  49. 6.9 ThromboGenics
  50. 6.9.1 ThromboGenics Company Information
  51. 6.9.2 ThromboGenics Business Overview
  52. 6.9.3 ThromboGenics Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 ThromboGenics Long-acting Retinal Drugs Product Portfolio
  54. 6.9.5 ThromboGenics Recent Developments
  55. 6.10 Regeneron
  56. 6.10.1 Regeneron Company Information
  57. 6.10.2 Regeneron Business Overview
  58. 6.10.3 Regeneron Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Regeneron Long-acting Retinal Drugs Product Portfolio
  60. 6.10.5 Regeneron Recent Developments
  61. 6.11 Oxurion NV
  62. 6.11.1 Oxurion NV Company Information
  63. 6.11.2 Oxurion NV Business Overview
  64. 6.11.3 Oxurion NV Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Oxurion NV Long-acting Retinal Drugs Product Portfolio
  66. 6.11.5 Oxurion NV Recent Developments
  67. 6.12 OncoGene Pharmaceuticals
  68. 6.12.1 OncoGene Pharmaceuticals Company Information
  69. 6.12.2 OncoGene Pharmaceuticals Business Overview
  70. 6.12.3 OncoGene Pharmaceuticals Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Portfolio
  72. 6.12.5 OncoGene Pharmaceuticals Recent Developments
  73. 6.13 MeiraGTx Limited
  74. 6.13.1 MeiraGTx Limited Company Information
  75. 6.13.2 MeiraGTx Limited Business Overview
  76. 6.13.3 MeiraGTx Limited Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 MeiraGTx Limited Long-acting Retinal Drugs Product Portfolio
  78. 6.13.5 MeiraGTx Limited Recent Developments
  79. 6.14 F. Hoffmann-La Roche
  80. 6.14.1 F. Hoffmann-La Roche Company Information
  81. 6.14.2 F. Hoffmann-La Roche Business Overview
  82. 6.14.3 F. Hoffmann-La Roche Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 F. Hoffmann-La Roche Long-acting Retinal Drugs Product Portfolio
  84. 6.14.5 F. Hoffmann-La Roche Recent Developments
  85. 6.15 Bausch Health Co. Inc.
  86. 6.15.1 Bausch Health Co. Inc. Company Information
  87. 6.15.2 Bausch Health Co. Inc. Business Overview
  88. 6.15.3 Bausch Health Co. Inc. Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Bausch Health Co. Inc. Long-acting Retinal Drugs Product Portfolio
  90. 6.15.5 Bausch Health Co. Inc. Recent Developments
  91. 6.16 Allergan
  92. 6.16.1 Allergan Company Information
  93. 6.16.2 Allergan Business Overview
  94. 6.16.3 Allergan Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Allergan Long-acting Retinal Drugs Product Portfolio
  96. 6.16.5 Allergan Recent Developments
  97. 6.17 Alimera Sciences Inc.
  98. 6.17.1 Alimera Sciences Inc. Company Information
  99. 6.17.2 Alimera Sciences Inc. Business Overview
  100. 6.17.3 Alimera Sciences Inc. Long-acting Retinal Drugs Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Alimera Sciences Inc. Long-acting Retinal Drugs Product Portfolio
  102. 6.17.5 Alimera Sciences Inc. Recent Developments
7 North America
  1. 7.1 North America Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Long-acting Retinal Drugs Market Size by Country (2021-2026)
  3. 7.3 North America Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Long-acting Retinal Drugs Market Size by Country (2021-2026)
  3. 8.3 Europe Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Long-acting Retinal Drugs Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Long-acting Retinal Drugs Market Size by Country (2021-2026)
  3. 10.3 South America Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Long-acting Retinal Drugs Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Long-acting Retinal Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst